Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug delivery
Pharma
EyePoint's Duravyu bounces back with promising DME data
EyePoint revitalized its star asset Duravyu with strong diabetic macular edema data, opening a path forward for other potential retinal indications.
Fraiser Kansteiner
Oct 28, 2024 1:11pm
PCI puts $365M-plus into multiple US, EU manufacturing projects
Sep 24, 2024 12:48pm
EyePoint's Yutiq production lands in the FDA's crosshairs
Aug 27, 2024 4:07pm
Amneal's new Parkinson's drug passes muster with US regulators
Aug 8, 2024 3:26am
Orexo's opioid overdose nasal spray is rejected again by FDA
Jul 17, 2024 10:47am
Biogen, Eisai kick off rolling FDA submission for subQ Leqembi
May 14, 2024 7:51pm
